Skip to content
Screener

BioCryst Pharmaceuticals BCRX Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost

Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost at other companies

Willis Towers Watson logo
Willis Towers WatsonWTW
$3.5M0.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$2.85M
Rackspace Technology, Inc. logo
Rackspace Technology, Inc.RXT
$25K
ACR
ACRES Commercial RealtyACR
$540K-33.7%
TDS
Telephone and Data SystemsTDS
$124.03M+6.6%
Carriage Services logo
Carriage ServicesCSV
$23.9M+0.5%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.51B+46.1%
Enterprise value$2.77B+46.6%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300

In December 2025, the Company extended the post-termination exercise period of certain vested stock option awards at the time of retirement for certain individuals to the original expiration date of the option awards. The Company considered this to be a modification of existing awards under ASC Topic 718, Compensation - Stock Compensation (“Topic 718”) and determined the incremental fair value associated with the modification using a binomial lattice model. In connection with the modification, the Company recognized incremental stock-based compensation expense of $2,848 and $6,432 during the three and six months ended June 30, 2026, respectively.

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost?
BioCryst Pharmaceuticals (BCRX) reported share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost of $2.85M in Q2 2026.
What does share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost mean?
Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost

Ask your AI about BioCryst Pharmaceuticals's share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude